Skip to main content
Premium Trial:

Request an Annual Quote

Should've Been Spotted Sooner

SARS-CoV-2 testing issues at a UK lab should have been caught faster, scientists tell the Guardian.

Earlier this month, officials suspended SARS-CoV-2 testing at Immensa Health Clinic's Wolverhampton location, following reports that a number of people tested positive for SARS-CoV-2 via lateral flow testing but then were negative by PCR analysis. According to GenomeWeb, the NHS Test and Trace program estimated that about 43,000 people received an incorrect negative PCR test result between Sept. 8 and Oct. 12.

The Guardian notes that neither Immensa nor the UK Health Security Agency noticed the discrepancies until academics and members of the public pointed them out. "You shouldn't be relying on anecdotal reports to spot a problem of this size," the University of Birmingham's Alan McNally tells the Guardian.

McNally adds there that PCR machines typically have controls that should alert those running the tests of failures and that labs should also check the data manually to spot, for instance, long stretches without any positive results.

"What is really surprising to me is that a problem like this was not picked up in the lab almost on the day," University College London's Deenan Pillay also tells the Guardian. "If anything looks strange, even if the number of positive tests goes down, then that is a clear red flag."

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.